Lessons from the Drug Discovery of Lapatinib, a Dual ErbB1/2 Tyrosine Kinase Inhibitor

Publisher： Bentham Science Publishers

E-ISSN： 1873-4294|6|5|435-460

ISSN： 1568-0266

Source： Current Topics in Medicinal Chemistry, Vol.6, Iss.5, 2006-03, pp. : 435-460

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Inhibitors of erbB-1 kinase

By  

Expert Opinion on Therapeutic Patents, Vol. 12, Iss. 12, 2002-12 ,pp. : 1903-1907

Informa Healthcare

Access to resources Recommend Favorite

A Comparative QSAR Analysis of Quinazoline Analogues as Tyrosine Kinase (erbB-2) Inhibitors

By  

Medicinal Chemistry, Vol. 7, Iss. 3, 2011-05 ,pp. : 200-212

Bentham Science Publishers

Access to resources Recommend Favorite

Cheminfomatic-based Drug Discovery of Human Tyrosine Kinase Inhibitors

By  

Current Topics in Medicinal Chemistry, Vol. 16, Iss. 13, 2016-05 ,pp. : 1452-1462

Bentham Science Publishers

Access to resources Recommend Favorite

Optimization and Therapeutic Activity of Liposome-Conjugated Monoclonal Antibodies Against the ErbB family of Receptor Tyrosine Kinases: First Step in the Development of Therapeutic Antibody/Liposomal Anticancer Drug Combinations

By  

Letters in Drug Design & Discovery, Vol. 3, Iss. 10, 2006-12 ,pp. : 704-713

Bentham Science Publishers

Access to resources Recommend Favorite

Lessons from Seven Decades of Antituberculosis Drug Discovery

By  

Current Topics in Medicinal Chemistry, Vol. 11, Iss. 10, 2011-05 ,pp. : 1216-1225

Bentham Science Publishers

Access to resources Recommend Favorite